source
- Vaxcyte's experimental pneumococcal vaccine VAX-31 meets Phase 3 endpoints, shares jump 35%Vaxcyte announced that its experimental pneumococcal vaccine VAX-31 achieved its primary objectives in a Phase 3 trial involving adult participants. The trial results showed that the vaccine met t…
- Eli Lilly's Jaypirca receives FDA approval for first-line treatment of untreated CLL and SLLEli Lilly announced that the FDA has approved its drug Jaypirca as a first‑line therapy for patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. The appr…